{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:47:16Z","timestamp":1776872836302,"version":"3.51.2"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.semerg.2026.102690","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:17:41Z","timestamp":1771636661000},"page":"102690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Documento de posicionamiento de SEMERGEN sobre la enfermedad renal cr\u00f3nica"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-8623","authenticated-orcid":false,"given":"N.","family":"P\u00e9rez-Le\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3655-7180","authenticated-orcid":false,"given":"J.","family":"Polo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"Alonso-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mart\u00ednez-Berganza-Asensio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 6","key":"10.1016\/j.semerg.2026.102690_bib0350","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1111\/dom.15747","article-title":"Cardiovascular and non-renal complications of chronic kidney disease: Managing risk","volume":"26","author":"Rossing","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semerg.2026.102690_bib0355","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2026.102690_bib0360","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.ajkd.2020.07.013","article-title":"Burden and cost of caring for US veterans with CKD: Initial findings from the VA renal information system (VA-REINS)","volume":"77","author":"Saran","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semerg.2026.102690_bib0365","first-page":"78","article-title":"Prevalence of chronic renal disease in Spain: results of the EPIRCE study","volume":"30","author":"Otero","year":"2010","journal-title":"Nefrologia"},{"key":"10.1016\/j.semerg.2026.102690_bib0370","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.nefroe.2018.04.010","article-title":"Chronic kidney disease in Spain: Prevalence and impact of accumulation of cardiovascular risk factors","volume":"38","author":"Gorostidi","year":"2018","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.semerg.2026.102690_bib0375","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.medcli.2020.03.005","article-title":"Prevalence of chronic kidney disease and associated factors in the Spanish population attended in primary care: Results of the IBERICAN study","volume":"156","author":"Llisterri","year":"2021","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.semerg.2026.102690_bib0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.nefro.2024.12.009","article-title":"Magnitude of chronic kidney disease in Spain","author":"Santamaria","year":"2025","journal-title":"Nefrologia"},{"issue":"Suppl 1","key":"10.1016\/j.semerg.2026.102690_bib0385","article-title":"#3667 REVEAL-CKD: Prevalence of undiagnosed stage 3 chronic kidney disease in Australia, Brazil Canada and Spain","volume":"38","author":"Pecoits-Filho","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.semerg.2026.102690_bib0390","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: An individual participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.semerg.2026.102690_bib0395","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.nefroe.2022.01.008","article-title":"Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain","volume":"41","author":"Escobar","year":"2021","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.semerg.2026.102690_bib0400","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/ckj\/sfac066","article-title":"Risk of outcomes in a Spanish population with chronic kidney disease","volume":"15","author":"Alc\u00e1zar","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.semerg.2026.102690_bib0405","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.jacc.2023.07.012","article-title":"Impaired Renal Function and Major Cardiovascular Events in Young Adults","volume":"82","author":"Hussain","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semerg.2026.102690_bib0410","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","article-title":"Burden of disease scenarios for 204 countries and territories, 2022-2050: A forecasting analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"issue":"Suppl 5","key":"10.1016\/j.semerg.2026.102690_bib0415","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes Management in Chronic Kidney Disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.semerg.2026.102690_bib0420","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: Challenges Progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semerg.2026.102690_bib0425","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","article-title":"Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme","volume":"40","author":"Jha","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.semerg.2026.102690_bib0430","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12913-021-06566-2","article-title":"Costs and healthcare utilisation of patients with chronic kidney disease in Spain","volume":"21","author":"Escobar","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.semerg.2026.102690_bib0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0297378","article-title":"Work disability and employment status among advanced chronic kidney disease patients","volume":"19","author":"Bay","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.semerg.2026.102690_bib0440","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"issue":"Suppl 4","key":"10.1016\/j.semerg.2026.102690_bib0445","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.semerg.2026.102690_bib0450","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12875-024-02638-4","article-title":"Chronic kidney disease in older adults: Challenges and opportunities for the primary care provider","volume":"25","author":"Brady","year":"2024","journal-title":"BMC Prim Care"},{"key":"10.1016\/j.semerg.2026.102690_bib0455","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/jcsm.13275","article-title":"Association between sarcopenia and frailty in elderly patients with chronic kidney disease","volume":"14","author":"Wang","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.semerg.2026.102690_bib0460","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: An Underappreciated Risk Factor for Cardiovascular Disease","volume":"13","author":"Barzilay","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"Suppl 1","key":"10.1016\/j.semerg.2026.102690_bib0465","first-page":"1","article-title":"Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology","volume":"45","author":"Montero","year":"2025","journal-title":"Nefrologia (Engl Ed)"},{"issue":"Suppl. 1","key":"10.1016\/j.semerg.2026.102690_bib0470","first-page":"S239","article-title":"Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semerg.2026.102690_bib0475","first-page":"223","article-title":"Documento de informaci\u00f3n y consenso para la detecci\u00f3n y manejo de la enfermedad renal cr\u00f3nica","volume":"42","author":"Ortiz","year":"2022","journal-title":"Nefrolog\u00eda"},{"issue":"Suppl 1","key":"10.1016\/j.semerg.2026.102690_bib0480","doi-asserted-by":"crossref","first-page":"i59","DOI":"10.1093\/ndt\/gfae258","article-title":"Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease","volume":"40","author":"Neuen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semerg.2026.102690_bib0485","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardio-vascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.semerg.2026.102690_bib0490","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2215\/CJN.0000000000000526","article-title":"Reframing chronicity with urgency in chronic kidney disease management","volume":"19","author":"Neuen","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semerg.2026.102690_bib0495","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12882-024-03652-5","article-title":"Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes","volume":"25","author":"Khan","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semerg.2026.102690_bib0500","article-title":"Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and Type 2 diabetes","author":"Zannad","year":"2024","journal-title":"J Intern Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0505","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3390\/cells12151975","article-title":"Slowing the Progression of Diabetic Kidney Disease","volume":"12","author":"Blazek","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.semerg.2026.102690_bib0510","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/ndt\/gfac331","article-title":"The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes","volume":"38","author":"Agarwal","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semerg.2026.102690_bib0515","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.nefro.2023.05.004","article-title":"Documento de consenso sobre el abordaje de la hiperpotasemia","volume":"43","author":"Ortiz","year":"2023","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.semerg.2026.102690_bib0520","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semerg.2026.102690_bib0525","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the EuropeanSociety of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semerg.2026.102690_bib0530","first-page":"310","article-title":"Practical use of new therapies for the management of dyslipidaemias Consensus SEC\/SEA\/SEEN\/SEMFYC\/SEMERGEN\/SEMG\/SEN\/SEACV\/S.E.N","volume":"59","author":"Vivas","year":"2024","journal-title":"REC: CardioClinics"},{"issue":"Suppl 1","key":"10.1016\/j.semerg.2026.102690_bib0535","first-page":"S128","article-title":"6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semerg.2026.102690_bib0540","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semerg.2026.102690_bib0545","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0550","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0555","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.medcli.2020.12.025","article-title":"Use of renin-angiotensin-aldosterone system blockade in controversial chronic kidney disease populations","volume":"156","author":"Garc\u00eda-Prieto","year":"2021","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.semerg.2026.102690_bib0560","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0565","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jamda.2021.10.019","article-title":"Effectiveness and Tolerance of Renin-Angiotensin System Inhibitors With Aging in Chronic Kidney Disease","volume":"23","author":"Villain","year":"2022","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.semerg.2026.102690_bib0570","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0575","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0580","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0585","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.nefroe.2023.09.002","article-title":"Finerenone: Towards a holistic therapeutic approach to patients with diabetic kidney disease","volume":"43","author":"G\u00f3rriz","year":"2023","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.semerg.2026.102690_bib0590","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0595","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0600","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semerg.2026.102690_bib0605","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: An exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semerg.2026.102690_bib0610","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0615","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0620","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semerg.2026.102690_bib0625","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2026.102690_bib0630","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomized placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2026.102690_bib0635","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0640","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: Pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.semerg.2026.102690_bib0645","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semerg.2026.102690_bib0650","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semerg.2026.102690_bib0655","article-title":"Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semerg.2026.102690_bib0660","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0665","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semerg.2026.102690_bib0670","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.662544","article-title":"Systematic review and meta-analysis of renin-angiotensin-aldosterone system blocker effects on the development of cardiovascular disease in patients with chronic kidney disease","volume":"12","author":"Yanai","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semerg.2026.102690_bib0675","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: A network meta-analysis of randomised clinical trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.semerg.2026.102690_bib0680","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A Bayesian net- work meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semerg.2026.102690_bib0685","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semerg.2026.102690_bib0690","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/ckj\/sfy105","article-title":"Impact of a phone app on nephrology referral","volume":"12","author":"Oliva-Damaso","year":"2018","journal-title":"Clin Kidney J"}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359326000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359326000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:53:01Z","timestamp":1776869581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359326000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1138359326000079"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2026.102690","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Documento de posicionamiento de SEMERGEN sobre la enfermedad renal cr\u00f3nica","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2026.102690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102690"}}